Limits...
Preliminary effects of oral uridine on the ocular surface in dry eye patients.

Chang KC, Oh JY, In YS, Kim MK, Shin KC, Wee WR, Lee JH, Park MG - J. Korean Med. Sci. (2009)

Bottom Line: The Schirmer wetting score for the oral uridine group was significantly increased (P=0.001, Wilcoxon signed rank test) at 3 months and its difference between two groups was statistically significant (P=0.030, Mann-Whitney U test).OSDI scores were significantly decreased at 1 and 3 months in treatment group.Oral uridine is effective in treatment of dry eyes.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea.

ABSTRACT
We designed a randomized, double blinded, 3-months controlled prospective clinical study to investigate effects of oral uridine on the ocular surface in dry eye patients. Twenty-seven patients who diagnosed as dry eye with lower than 5 mm of wetting in the Schirmer strip, with corneal epithelial erosion and who completely followed-up till 3 months were enrolled. Corneal-conjunctival fluorescein staining, non-anesthetic Schirmer test, impression cytology, and Ocular Surface Disease Index (OSDI) were evaluated in the experimental and placebo groups at the baseline, 1 and 3 months after start of medication in a double blinded manner. Fluorescein stain score of the cornea was markedly decreased in oral uridine group compared to the placebo group at 3 months after medication (P=0.032, Mann-Whitney U test). The Schirmer wetting score for the oral uridine group was significantly increased (P=0.001, Wilcoxon signed rank test) at 3 months and its difference between two groups was statistically significant (P=0.030, Mann-Whitney U test). OSDI scores were significantly decreased at 1 and 3 months in treatment group. Oral uridine is effective in treatment of dry eyes.

Show MeSH

Related in: MedlinePlus

Change within each group of oral uridine and placebo in conjunctival and corneal fluorescein staining (A), aqueous tear production (B), conjunctival goblet cell density (C) and Ocular Surface Disease Index (OSDI) (D). Data are expressed as mean±SD.*P<0.01; †P=0.044 (Wilcoxon signed rank test).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2719204&req=5

Figure 1: Change within each group of oral uridine and placebo in conjunctival and corneal fluorescein staining (A), aqueous tear production (B), conjunctival goblet cell density (C) and Ocular Surface Disease Index (OSDI) (D). Data are expressed as mean±SD.*P<0.01; †P=0.044 (Wilcoxon signed rank test).

Mentions: For the oral urdine treatment group, the post-treatment corneal fluorescein staining scores, after 1 and 3 months of medication, were significantly lower than those obtained at the baseline (P=0.004 and P<0.001 for 1 and 3-months of medication, Wilcoxon signed rank test). This reduction was significantly lower in the placebo group (P=0.070 and 0.117 for 1 and 3-months of medication, Wilcoxon signed rank test) (Fig. 1A). The fluorescein staining score was markedly decreased in the oral uridine group compared to the placebo group at 3-months after treatment (P=0.032, Mann-Whitney U test) (Fig. 2A). There was a moderate correlation (oral uridine group, ρ=0.449 (P=0.093) and 0.607 (P=0.016) for 1 and 3-months of medication; placebo group, ρ=0.751 (P=0.008) and 0.653 (P=0.029) for 1 and 3-months of medication) and no significant difference between right and left eye within each both group (oral uridine group, P=0.642 and 0.439 for 1 and 3-months of medication; placebo group, P=0.946 and 0.606 for 1 and 3-months of medication).


Preliminary effects of oral uridine on the ocular surface in dry eye patients.

Chang KC, Oh JY, In YS, Kim MK, Shin KC, Wee WR, Lee JH, Park MG - J. Korean Med. Sci. (2009)

Change within each group of oral uridine and placebo in conjunctival and corneal fluorescein staining (A), aqueous tear production (B), conjunctival goblet cell density (C) and Ocular Surface Disease Index (OSDI) (D). Data are expressed as mean±SD.*P<0.01; †P=0.044 (Wilcoxon signed rank test).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2719204&req=5

Figure 1: Change within each group of oral uridine and placebo in conjunctival and corneal fluorescein staining (A), aqueous tear production (B), conjunctival goblet cell density (C) and Ocular Surface Disease Index (OSDI) (D). Data are expressed as mean±SD.*P<0.01; †P=0.044 (Wilcoxon signed rank test).
Mentions: For the oral urdine treatment group, the post-treatment corneal fluorescein staining scores, after 1 and 3 months of medication, were significantly lower than those obtained at the baseline (P=0.004 and P<0.001 for 1 and 3-months of medication, Wilcoxon signed rank test). This reduction was significantly lower in the placebo group (P=0.070 and 0.117 for 1 and 3-months of medication, Wilcoxon signed rank test) (Fig. 1A). The fluorescein staining score was markedly decreased in the oral uridine group compared to the placebo group at 3-months after treatment (P=0.032, Mann-Whitney U test) (Fig. 2A). There was a moderate correlation (oral uridine group, ρ=0.449 (P=0.093) and 0.607 (P=0.016) for 1 and 3-months of medication; placebo group, ρ=0.751 (P=0.008) and 0.653 (P=0.029) for 1 and 3-months of medication) and no significant difference between right and left eye within each both group (oral uridine group, P=0.642 and 0.439 for 1 and 3-months of medication; placebo group, P=0.946 and 0.606 for 1 and 3-months of medication).

Bottom Line: The Schirmer wetting score for the oral uridine group was significantly increased (P=0.001, Wilcoxon signed rank test) at 3 months and its difference between two groups was statistically significant (P=0.030, Mann-Whitney U test).OSDI scores were significantly decreased at 1 and 3 months in treatment group.Oral uridine is effective in treatment of dry eyes.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea.

ABSTRACT
We designed a randomized, double blinded, 3-months controlled prospective clinical study to investigate effects of oral uridine on the ocular surface in dry eye patients. Twenty-seven patients who diagnosed as dry eye with lower than 5 mm of wetting in the Schirmer strip, with corneal epithelial erosion and who completely followed-up till 3 months were enrolled. Corneal-conjunctival fluorescein staining, non-anesthetic Schirmer test, impression cytology, and Ocular Surface Disease Index (OSDI) were evaluated in the experimental and placebo groups at the baseline, 1 and 3 months after start of medication in a double blinded manner. Fluorescein stain score of the cornea was markedly decreased in oral uridine group compared to the placebo group at 3 months after medication (P=0.032, Mann-Whitney U test). The Schirmer wetting score for the oral uridine group was significantly increased (P=0.001, Wilcoxon signed rank test) at 3 months and its difference between two groups was statistically significant (P=0.030, Mann-Whitney U test). OSDI scores were significantly decreased at 1 and 3 months in treatment group. Oral uridine is effective in treatment of dry eyes.

Show MeSH
Related in: MedlinePlus